Vanguard Group Inc. lifted its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 2.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,048,152 shares of the company's stock after acquiring an additional 20,341 shares during the period. Vanguard Group Inc. owned 0.63% of Dr. Reddy's Laboratories worth $70,090,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently made changes to their positions in RDY. Citigroup Inc. lifted its stake in Dr. Reddy's Laboratories by 11.3% during the third quarter. Citigroup Inc. now owns 57,637 shares of the company's stock valued at $3,854,000 after purchasing an additional 5,868 shares during the last quarter. Wellington Management Group LLP lifted its stake in Dr. Reddy's Laboratories by 40.7% during the third quarter. Wellington Management Group LLP now owns 141,154 shares of the company's stock valued at $9,439,000 after purchasing an additional 40,825 shares during the last quarter. American Century Companies Inc. lifted its stake in Dr. Reddy's Laboratories by 13.2% during the third quarter. American Century Companies Inc. now owns 102,497 shares of the company's stock valued at $6,854,000 after purchasing an additional 11,930 shares during the last quarter. Graham Capital Management L.P. acquired a new stake in shares of Dr. Reddy's Laboratories during the third quarter valued at approximately $265,000. Finally, Walleye Capital LLC acquired a new stake in shares of Dr. Reddy's Laboratories during the third quarter valued at approximately $7,433,000. 14.02% of the stock is owned by institutional investors and hedge funds.
Dr. Reddy's Laboratories Stock Up 1.2 %
Dr. Reddy's Laboratories stock traded up $0.88 during trading hours on Friday, hitting $73.76. The company had a trading volume of 160,240 shares, compared to its average volume of 170,047. The firm has a market capitalization of $12.31 billion, a P/E ratio of 19.46, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90. The firm's fifty day moving average is $74.48 and its 200-day moving average is $69.86. Dr. Reddy's Laboratories Limited has a fifty-two week low of $53.12 and a fifty-two week high of $77.72.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Wednesday, January 31st. The company reported $0.99 EPS for the quarter, topping the consensus estimate of $0.88 by $0.11. The company had revenue of $867.00 million during the quarter, compared to the consensus estimate of $827.81 million. Dr. Reddy's Laboratories had a net margin of 19.26% and a return on equity of 20.97%. On average, research analysts forecast that Dr. Reddy's Laboratories Limited will post 3.96 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. Barclays boosted their price target on shares of Dr. Reddy's Laboratories from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, January 29th. StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "strong-buy" rating in a report on Friday. Finally, Jefferies Financial Group lowered shares of Dr. Reddy's Laboratories from a "buy" rating to an "underperform" rating in a report on Thursday, January 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $80.00.
Get Our Latest Analysis on Dr. Reddy's Laboratories
About Dr. Reddy's Laboratories
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.
See Also
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
